CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

2026-04-23

MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, enables once-every-4-weeks dosing (whereas currently marketed drugs targeting the same pathway require dosing once every 2 weeks), which may improve treatment adherence. It is also expected to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, demonstrating BIC potential. In a Phase III clinical trial in adult patients with moderate-to-severe SAR, MG-K10 has met the primary endpoint, demonstrating significantly superior efficacy compared with the placebo group, with a favorable safety profile. The acceptance of the NDA represents an important milestone for CMS Vision(the ophthalmology business) in expanding its therapeutic focus from ophthalmology into the field of ENT, and also marks another significant milestone in the Group’s R&D progress in the field of type 2 inflammatory diseases.     China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic […]

CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year

2026-04-14

S&P Global, an internationally recognized rating agency, recently released the Sustainability Yearbook (China Edition) 2026. China Medical System (“CMS” or the “Group”) stood out among nearly 1,800 companies and was successfully included for the fourth consecutive year, underscoring the Group’s long-term resilience and comprehensive strengths in sustainable development. (Source:S&P Global)   CMS integrates the United Nations Sustainable Development Goals (“SDGs”) into the Group’s ESG strategy, guided by top-level planning, is driving a more sustainable transformation across the entire value chain. We are committed to improving accessibility and equity in healthcare, and continue to increase R&D investment in innovative medicines and treatments for rare diseases, addressing unmet clinical needs through scientific innovation. At the same time, we remain dedicated to inclusive healthcare, responding to societal needs through concrete actions and fulfilling the responsibilities expected of a pharmaceutical company. We also place strong emphasis on employee development and environmental protection, and steadily advance our responsible practices.   The Group’s […]